Industry Satellite Symposia

IAP 2022 will include the following engaging sponsored sessions.

Please RSVP to the details provided for the session/s that you are interested in.

Lunchtime Session:

Date: Tuesday 11^th October

Sponsored by: Roche

Speaker 1: Dr Jeremy Parry

Speaker 2: A/Prof Simon Nazaretian

Title: Demystifying Artificial Intelligence in Image Analysis Algorithms

Click here to register

Breakfast Session

Date: Saturday 15^th October

Sponsored by: AstraZeneca

Speaker: Prof Gelareh Farshid

Title: Understanding the fundamentals of HER2 testing in breast cancer

Click here to register

Breakfast Session

Date: Friday 14 October 2022

Sponsored by: Roche

Speaker 1: Dr Cameron Snell

Title: Applying algorithm-assisted assessment of HER 2 ISH to reduce interobserver variability

Click here to register

Speaker 2: Madeline Gough

Lunchtime Session

Date: Friday 14 October 2022

Sponsored by: Agilent Technologies

Speaker 1: Professor Stephen Fox, BSc (Hons), MBChB, FRCPath, FFSc, FRCPA, DPhil

Director of Pathology, Peter MacCallum Cancer Centre

Professorial Fellow, University of Melbourne

Title: Current, Emerging Biomarkers and Immuno-oncology

Speaker 2: Dan Belluoccio, Ph.D

Sr. Field Applications Scientist, Diagnostics and Genomics Group

Agilent Technologies

Title: SureSelect Cancer CGP Assay for Detection of the Common Mutation Types Found in Cancer

Click here to register

Lunchtime Session

Date: Friday 14^th October

Sponsored by: AstraZeneca

Speaker: Prof Gelareh Farshid

Title: Understanding the fundamentals of HER2 testing in breast cancer

Click here to register

Lunchtime Session

Date: Thursday 13 October 2022

Sponsored by: Illumina

Speaker 1: Dr Tim Humphries

Title: TMB Assessment Through NGS: Biomarker thresholds for Complete Response in Melanoma using the TSO 500

Click here to register

Speaker 2: Dr Tino Giardina

Title: Assessment of Tissue and Blood Tumor Mutational Burden in Patients with Melanoma using a 523-gene Clinical Assay.

Patricia Chevez-Barrios

After finishing all seven of her postdoctoral training programs, Dr. Chévez-Barrios joined the faculty of the Baylor College of Medicine in 1996 as an Assistant Professor in the Department of Pathology, with a secondary appointment in the Department of Ophthalmology. She became a Clinical Assistant Professor in the Department of Ophthalmology there in 2004, and received the Fulbright & Jaworski LLP Award for Faculty Excellence in Teaching and Evaluation and became Associate Member of the Cell and Gene Therapy Center that same year. She has current appointments of adjunct professor in the Department of Pathology at The University of Texas MD Anderson Cancer Center and Department of Ophthalmology at the Baylor College of Medicine. Dr. Chévez- Barrios assumed her current positions at Methodist in 2004.

The main research interest of Dr. Chévez-Barrios and her laboratory is the study of retinoblastoma, including cancer stem cells, suicide gene therapy for retinoblastoma, the study of metastatic properties of retinoblastoma and preclinical models of the tumor. Other topics of interest are ocular gene therapy, cataractogenesis, vascular proliferation in hypoxic ocular diseases and corneal diseases. Dr. Chevez-Barrios’ laboratory is currently participating in the project of gene therapy for Retinoblastomas in collaboration with the Texas Children’s Cancer Center and the Center for Gene Therapy of Texas Children's Hospital, and Baylor College of Medicine. Pre-clinical studies and a phase 1 clinical trial of vitreous seed of retinoblastoma have been completed. The phase II clinical trial is in preparation. Dr. Chevez-Barrios is a committee member responsible of evaluating all enucleated eyes from the prospective multicenter study of the ARET0332 Children’s Oncology Group protocol on “A Study of Unilateral Retinoblastoma With and Without Histopathologic High-Risk Features and the Role of Adjuvant Chemotherapy. Dr. Chevez-Barrios is also interested in the biological differences between retinoblastoma cell lines that have the capability of producing metastasis, and those that behave less aggressively and remain as intraocular tumors.

Rondell P. Graham

Rondell P. Graham, M.B.B.S., studies the molecular genetics of liver tumors with a focus on biomarkers for diagnosis, treatment and classification of tumors. His work seeks to understand how liver tumors develop and progress. The long-term intent is to identify targets that define specific subtypes of liver tumors and also targets that can be treated with rational approaches to improve the outcome of patients affected by liver tumors.

Dr. Graham works with a team of investigators using a combination of traditional and novel histologic, molecular and proteomic approaches. This collaborative effort evaluates liver tumors, including fibrolamellar carcinoma, hepatocellular carcinoma and hepatocellular adenomas, in order to refine the understanding and classification of liver tumors.

Focus areas

To determine how pathologists can provide a better diagnosis of subtypes of hepatocellular carcinoma such as fibrolamellar carcinoma. Currently, the classification of subtypes of hepatocellular carcinoma is based on histologic rounds. This system has many benefits and has served clinical care effectively for some time. However, the key genetic driver of several subtypes of hepatocellular carcinoma and the genetic — histologic correlations of hepatocellular carcinoma are understudied. Dr. Graham is working to improve the genetic-histologic correlation of hepatocellular carcinoma subtypes. This has the potential to lead to improved diagnosis.
To identify the key biomarkers needed for fibrolamellar carcinoma progression. Fibrolamellar carcinoma affects young patients without underlying chronic liver disease and has an unfavorable prognosis if surgical resection is not possible. A unique genetic event has been found in fibrolamellar carcinoma but the mechanism for tumor progression is unknown. Dr. Graham and his team are performing a comprehensive, detailed characterization of fibrolamellar carcinomas in order to understand how the tumor cells function and progress. The goal of this work is to identify targets that can be treated and lead to improved clinical outcomes.

Simone Louise Van Es

Dr Van Es is a medical graduate from the University of Sydney (1991) and is a Fellow of the Royal College of Pathologists of Australasia (Anatomical Pathology). After her intern and RMO years at Royal Prince Alfred Hospital, she spent 12 months working in palliative care medicine and general practice, followed by several years working in Sexual Health Medicine. After this Dr Van Es pursued postgraduate specialist training in Anatomical Pathology/Cytopathology. Dr Van Es obtained her Fellowship with the Royal College of Pathologists of Australasia (Anatomical Pathology/Cytopathology) in 2003. She worked as a consultant dermatopathologist for several years and also held a fractional postgraduate Fellowship position in Melanoma Pathology in 2005.

Dr Van Es has worked as a lecturer in Pathology with the School of Medical Sciences (SOMS), UNSW Medicine, since 2008. She received the SOMS contribution to the student experience award in 2010. In 2013 Dr Van Es was recipient of the Pathology Day Prize from the RCPA (Royal College of Pathologists of Australasia) for the teaching and quizzes organised at UNSW for Pathology Day 2013. For International Pathology Day in 2014, Dr Van Es authored the RCPA Pathology Day Quiz (a complex quiz on the selection and interpretation of pathology tests and their clinical application) for medical students and Pathology trainees throughout Australia. In 2019, she was awarded a Fellowship of the Faculty of Science for scientific achievement by The Royal College of Pathologists of Australasia (RCPA).

To date, Dr Van Es is responsible for the creation of over 250 histopathology and cytopathology whole slide images, which are hosted on the BEST (Biomedical Education, Skills and Training) Network virtual slide repository. This virtual slide repository is a teaching resource that is used by institutions throughout Australia. Dr Van Es also has accumulated experience authoring VMATs (virtual microscopy adaptive tutorials). These virtual slides and VMATs have formed the basis of Dr Van Es' research and teaching both for UNSW and external pathology institutions (Royal College of Pathologists of Australasia).

Dr Van Es obtained her PhD in Digital Pathology in 2015. Since this time, in addition to her work at UNSW, she has continued to collaborate on projects with the Royal College of Pathologists of Australasia (RCPA) and the Royal College of Pathologists of Australasia Quality Assurance Programs (RCPAQAP) in digital pathology and online education in histopathology and cytopathology.

Aleodor (Doru) Andea

Aleodor (Doru) Andea, MD, MBA, is a Professor of Pathology and Dermatology and Director of the Dermatopathology Fellowship at the University of Michigan in Ann Arbor, MI. Dr. Andea's areas of expertise are Dermatopathology and Molecular Pathology. Dr. Andea received his MD from "Victor Babes" University of Medicine, Timisoara, Romania and completed an Anatomic and Clinical Pathology Residency at Wayne State University in Detroit, Michigan. This was followed by fellowships in Dermatopathology at Medical University of South Carolina, Charleston, SC and Oncologic Pathology and Molecular Pathology at Memorial Sloan-Kettering Cancer Center, New York, NY. After completing his training Dr Andea joined the faculty of the Department of Pathology at the University of Alabama at Birmingham (UAB) where he served as Director of the Dermatopathology Fellowship program, Medical Director of the In-situ Hybridization Laboratory and as Dermatopathology Section Head. In 2009 Dr. Andea received the "Leonard H. Robinson" Award for Excellence in Resident Education in Anatomic Pathology. At UAB Dr. Andea developed a research interest in the molecular biology of melanocytic neoplasms and precision molecular diagnostic tests for histologically ambiguous melanocytic tumors. While at UAB, Dr. Andea earned a Master of Business Administration degree from UAB School of Business.

At the University of Michigan Dr. Andea has established and is leading the Molecular Dermatopathology Research Laboratory which functions as a dermatopathology core facility for skin cancer research and the Dermatopathology Molecular Diagnostics Laboratory providing clinical testing for melanocytic tumors. Dr Andea has a particular interest in developing and improving ancillary molecular tests to help classify and predict prognosis in histologically ambiguous melanocytic tumors. As a side hobby he enjoys playing with digital pathology tools and is interested in exploring the potential for implementation of virtual pathology into clinical work. He was invited to deliver numerous national and international presentations on a variety of dermatopathology topics, with a focus on molecular diagnostic tools for melanocytic tumors and digital pathology. Dr. Andea is the author of over 60 peer-reviewed publications, over 100 abstracts and one book chapter, mainly in the field of dermatopathology. Outside of pathology he enjoys skiing and swimming.

Wendy Raymond

Associate Professor Wendy Raymond qualified in Medicine at the University of Adelaide Medical School in 1986 and went on to specialise in anatomical pathology, gaining her research degree (MD) on “Prognostic markers in breast cancer” in 1991, and her Fellowship of the Royal College of Pathologists of Australasia in 1992. Her pathology training involved appointments in Adelaide and in Manchester, UK, before she returned to South Australia as a Consultant Histopathologist at Flinders Medical Centre and Senior Lecturer at Flinders University of South Australia.

She held a Visiting Consultant appointment as Cytopathologist at BreastScreen SA (1998-2015), and worked part-time as a Specialist Pathologist for Drs King and Mower Pathology and subsequently Healthscope Pathology, from 2005-2014.

She also continued as a part-time specialist at Flinders Medical Centre (SA Pathology) and, since 2010, has held the academic title of Associate Professor in the School of Medicine, Flinders University. A/Prof Raymond was Senior Pathologist, Head of Unit, at BreastScreen SA 2012-2015. In 2012, she was awarded Fellowship of the International Academy of Cytology. She has held roles of Anatomical Pathology examiner and Cancer Services and Cytopathology Advisory Committee member for The Royal College of Pathologists of Australasia. She is a Past President of the Australasian Society of Breast Disease and of the Australian Society of Cytology. She has been actively involved in national breast cancer reporting guidelines, implementation of HER 2 assessment and quality assurance committees and is currently Chair of the Breast Pathology Quality Assurance Committee.

A/Prof Raymond has a particular interest and expertise in breast and endocrine histopathology, fine needle aspiration and general cytopathology, and has published widely in these areas, including co-editing the recent IAC Yokohama System for Reporting Breast Fine needle aspiration biopsy Cytopathology.